JP2021533098A5 - - Google Patents

Info

Publication number
JP2021533098A5
JP2021533098A5 JP2021504376A JP2021504376A JP2021533098A5 JP 2021533098 A5 JP2021533098 A5 JP 2021533098A5 JP 2021504376 A JP2021504376 A JP 2021504376A JP 2021504376 A JP2021504376 A JP 2021504376A JP 2021533098 A5 JP2021533098 A5 JP 2021533098A5
Authority
JP
Japan
Prior art keywords
composition according
aav vector
seq
aav
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021504376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533098A (ja
JP7684212B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044946 external-priority patent/WO2020028830A1/en
Publication of JP2021533098A publication Critical patent/JP2021533098A/ja
Publication of JP2021533098A5 publication Critical patent/JP2021533098A5/ja
Application granted granted Critical
Publication of JP7684212B2 publication Critical patent/JP7684212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504376A 2018-08-03 2019-08-02 第viii因子の発現による改善された臨床パラメーター Active JP7684212B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862714553P 2018-08-03 2018-08-03
US62/714,553 2018-08-03
US201962826887P 2019-03-29 2019-03-29
US62/826,887 2019-03-29
US201962869445P 2019-07-01 2019-07-01
US62/869,445 2019-07-01
PCT/US2019/044946 WO2020028830A1 (en) 2018-08-03 2019-08-02 Improved clinical parameters by expression of factor viii

Publications (3)

Publication Number Publication Date
JP2021533098A JP2021533098A (ja) 2021-12-02
JP2021533098A5 true JP2021533098A5 (cg-RX-API-DMAC7.html) 2022-08-09
JP7684212B2 JP7684212B2 (ja) 2025-05-27

Family

ID=69230742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504376A Active JP7684212B2 (ja) 2018-08-03 2019-08-02 第viii因子の発現による改善された臨床パラメーター

Country Status (11)

Country Link
US (1) US12497632B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829650A4 (cg-RX-API-DMAC7.html)
JP (1) JP7684212B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210039428A (cg-RX-API-DMAC7.html)
CN (1) CN112533645B (cg-RX-API-DMAC7.html)
AU (1) AU2019314513B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001315A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105382A1 (cg-RX-API-DMAC7.html)
IL (1) IL280402B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001375A (cg-RX-API-DMAC7.html)
WO (1) WO2020028830A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303737A (en) * 2020-12-18 2023-08-01 Sangamo Therapeutics Inc Improved pharmaceutical compositions containing adeno-associated viral vector

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024479A1 (en) 1996-12-02 1998-06-11 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
CA2392863A1 (en) 2002-07-08 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A high capacity recombinant adenoviral vector for treatment of hemophilia a
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
JPWO2006043354A1 (ja) 2004-10-20 2008-05-22 独立行政法人放射線医学総合研究所 組込型の低線量放射線誘導性ベクター
WO2007021353A2 (en) 2005-06-10 2007-02-22 Genentech, Inc. Improving antibody expression using vectors containing insulator elements
CA2703948A1 (en) 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US9617548B2 (en) 2008-04-22 2017-04-11 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
WO2009134681A2 (en) * 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
EP2758529B1 (en) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
ES2923757T3 (es) * 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
WO2014043131A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
MX2015013842A (es) 2013-03-30 2017-01-23 Usha Biotech Ltd Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
ES2813698T3 (es) 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
CA3229275A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
UA124491C2 (uk) 2015-05-11 2021-09-29 Баєр Кропсаєнс Акціенгезельшафт Комбінації гербіцидів, які містять l-глюфосинат та індазифлам
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
JP2018535929A (ja) 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
US10143760B2 (en) * 2015-10-28 2018-12-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
US20200237930A1 (en) * 2017-08-01 2020-07-30 Spark Therapeutics, Inc. Factor viii (fviii) gene therapy methods

Similar Documents

Publication Publication Date Title
JP2024054426A5 (cg-RX-API-DMAC7.html)
JP2023538519A5 (cg-RX-API-DMAC7.html)
JP2022141670A5 (cg-RX-API-DMAC7.html)
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2023070682A5 (cg-RX-API-DMAC7.html)
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP2020514286A5 (cg-RX-API-DMAC7.html)
JP2021536244A5 (cg-RX-API-DMAC7.html)
JP2020518268A5 (cg-RX-API-DMAC7.html)
JP2022516283A5 (cg-RX-API-DMAC7.html)
JP2019513794A5 (cg-RX-API-DMAC7.html)
JP2023517934A5 (cg-RX-API-DMAC7.html)
JP2021522842A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
JP2021500922A5 (cg-RX-API-DMAC7.html)
JP2020519292A5 (cg-RX-API-DMAC7.html)
JP2024056832A5 (cg-RX-API-DMAC7.html)
JP2024545183A5 (cg-RX-API-DMAC7.html)
JP2023520402A5 (cg-RX-API-DMAC7.html)
JP2022513318A5 (cg-RX-API-DMAC7.html)
JP2023534037A5 (cg-RX-API-DMAC7.html)
JP2024546103A5 (cg-RX-API-DMAC7.html)
JP2022505877A5 (cg-RX-API-DMAC7.html)
JP2024527742A5 (cg-RX-API-DMAC7.html)
JP2024545186A5 (cg-RX-API-DMAC7.html)